In 2022, the FDA approved tirzepatide for T2D therapy beneath the model identify Mounjaro determined by the SURPASS software effects, which demonstrated a discount of as much as -3.02% in glycated hemoglobin. It is actually administered in weekly doses of as much as 15mg [one, 30]. Tirzepatide has a